<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333343</url>
  </required_header>
  <id_info>
    <org_study_id>CEGF816X2102</org_study_id>
    <secondary_id>2017-002496-25</secondary_id>
    <nct_id>NCT03333343</nct_id>
  </id_info>
  <brief_title>Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC</brief_title>
  <official_title>A Phase Ib, Open Label, Multi-center Study to Characterize the Safety, Tolerability and Preliminary Efficacy of EGF816 in Combination With Selected Targeted Agents in EGFR Mutant NSCLC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the&#xD;
      addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients&#xD;
      with advanced EGFR-mutant NSCLC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase Ib, open label, non-randomized dose escalation study of EGF816 in combination&#xD;
      with ribociclib, trametinib, or LXH254, followed by dose expansion of EGF816 in combination&#xD;
      with ribociclib, trametinib, LXH254, INC280, or gefitinib in adult patients with advanced&#xD;
      EGFR-mutant NSCLC.&#xD;
&#xD;
      During the dose escalation part, patients will be assigned to the addition of trametinib,&#xD;
      ribociclib, or LXH254 to EGF816.&#xD;
&#xD;
      Following determination of the recommended dose for the combination of EGF816 + trametinib,&#xD;
      EGF816 + ribociclib, and EGF816 + LXH254, patients may be enrolled to the dose expansion arms&#xD;
      of each of these combinations. Patients may also be assigned to EGF816 + INC280 or EGF816 +&#xD;
      gefitinib in dose expansion.&#xD;
&#xD;
      Efficacy assessments will be performed at baseline and every 2 cycles during treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 29, 2018</start_date>
  <completion_date type="Anticipated">November 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events and serious adverse events</measure>
    <time_frame>Every day until study end, approximately 4 years</time_frame>
    <description>Assess safety and tolerability including incidence of dose limiting toxicities, adverse events, and serious adverse events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR2</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Modified objective response rate (ORR2) per RECIST v1.1 (taking as baseline the most recent assessment prior to initiating combination)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Overall response rate (ORR) per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Time from the date of first dose of study treatment to the date of first documented disease progression (per RECIST v1.1) or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Proportion of patients with best overall response of CR, PR, or SD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
    <description>Time from first documented response (PR or CR) to the date of first documented disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to response</measure>
    <time_frame>Every 8-12 weeks until study ends, approximately 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">105</enrollment>
  <condition>EGFR-mutant Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816+ trametinib in escalation phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + ribociclib in escalation phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + LXH254 in escalation phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + INC280 in expansion phase (patients with no known resistance mechanism)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + trametinib in expansion phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + ribociclib in expansion phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + LXH254 in expansion phase (patients with no known resistance mechanism)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + LXH254 in expansion phase (patients with known resistance mechanism)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + gefitinib in expansion phase</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGF816 + INC280 in expansion phase (patients with known resistance mechanism)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGF816</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
    <arm_group_label>Arm F</arm_group_label>
    <arm_group_label>Arm G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trametinib</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ribociclib</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LXH254</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm 3</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_label>Arm E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INC280</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gefitinib</intervention_name>
    <description>Study Drug</description>
    <arm_group_label>Arm F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically or cytologically confirmed locally advanced (stage&#xD;
             IIIB) or metastatic (stage IV) EGFR mutant (ex19del, L858R) NSCLC.&#xD;
&#xD;
          -  Requirements of EGFR mutation status and prior lines of treatment:&#xD;
&#xD;
          -  Treatment naive patients, who have locally advanced or metastatic NSCLC with EGFR&#xD;
             sensitizing mutation (e.g., L858R and/or ex19del), have not received any systemic&#xD;
             antineoplastic therapy for advanced NSCLC and are eligible to receive EGFR TKI&#xD;
             treatment. Patients with EGFR exon 20 insertion/duplication are not eligible. Note:&#xD;
             patients who have received only one cycle of chemotherapy in the advanced setting are&#xD;
             allowed.&#xD;
&#xD;
          -  Patients who have locally advanced or metastatic NSCLC with EGFR sensitizing mutation&#xD;
             AND an acquired T790M mutation (e.g., L858R and/or ex19del, T790M+) following&#xD;
             progression on prior treatment with a 1st-generation EGFR TKI or 2nd-generation EGFR&#xD;
             TKI. These patients may not have received more than 4 prior lines of antineoplastic&#xD;
             therapy in the advanced setting, including EGFR TKI, and may not have received any&#xD;
             agent targeting EGFR T790M mutation (i.e., 3rd-generation EGFR TKI).&#xD;
&#xD;
          -  Patients who have locally advanced or metastatic NSCLC with EGFR sensitizing mutation&#xD;
             and a &quot;de novo&quot; T790M mutation (i.e., no prior treatment with any agent known to&#xD;
             inhibit EGFR including EGFR TKI). These patients may not have received more than 3&#xD;
             prior lines of antineoplastic therapy in the advanced setting, and may not have&#xD;
             received any prior 3rd generation EGFR TKI.&#xD;
&#xD;
          -  Patients must have a site of disease amenable to biopsy, and be a candidate for tumor&#xD;
             biopsy according to the treating institution's guidelines. Patients must be willing to&#xD;
             undergo a new tumor biopsy during therapy on this study, and at screening if an&#xD;
             archival tumor sample obtained since the diagnosis of advanced disease (1L patients)&#xD;
             or since last treatment failure (2L+ patients) is not available.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a history or presence of interstitial lung disease or interstitial&#xD;
             pneumonitis, including clinically significant radiation pneumonitis.&#xD;
&#xD;
          -  Patients with unstable brain metastases.&#xD;
&#xD;
          -  Patients with a history of another malignancy.&#xD;
&#xD;
          -  Patients with a known history of human immunodeficiency virus (HIV) seropositivity.&#xD;
&#xD;
          -  Patients with clinically significant, uncontrolled heart disease.&#xD;
&#xD;
          -  Patients participating in additional parallel investigational drug or medical device&#xD;
             studies.&#xD;
&#xD;
          -  Prior therapies:&#xD;
&#xD;
          -  Patients who have been treated with EGFR TKI in the adjuvant setting within 6 months,&#xD;
             unless acquired EGFR T790M is present in a tumor or blood sample obtained since the&#xD;
             discontinuation of the EGFR TKI.&#xD;
&#xD;
          -  Patients who have been treated with prior EGFR TKI targeting T790M (3rd generation).&#xD;
&#xD;
          -  Patients who have been treated with systemic anti-neoplastic therapy within:&#xD;
&#xD;
               -  2 weeks for fluoropyrimidine monotherapy&#xD;
&#xD;
               -  6 weeks for nitrosoureas and mitomycin&#xD;
&#xD;
               -  4 weeks or ≤ 5 half-lives (whichever is shorter) for biological therapy&#xD;
                  (including monoclonal antibodies) and continuous or intermittent small molecule&#xD;
                  therapeutics or any other investigational agent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Chair</role>
    <affiliation>Novartis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119228</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Singapore</country>
    <country>Taiwan</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>June 22, 2021</last_update_submitted>
  <last_update_submitted_qc>June 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR-mutant NSCLC</keyword>
  <keyword>EGF816</keyword>
  <keyword>LXH254</keyword>
  <keyword>INC280</keyword>
  <keyword>ribociclib</keyword>
  <keyword>trametinib</keyword>
  <keyword>gefitinib</keyword>
  <keyword>EGFR T790M</keyword>
  <keyword>BRAF mutation</keyword>
  <keyword>BRAF fusion</keyword>
  <keyword>BRAF rearrangement</keyword>
  <keyword>MET amplification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gefitinib</mesh_term>
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Nazartinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

